. 2015 Feb 25;24(13):1521–1535. doi: 10.1089/scd.2014.0588

Table 4.

Relationships Between Immunohistochemical Expression and Clinicopathologic Parameters in Ovarian Serous Carcinoma (n=74)

	FOXA2		LEF1		VAV3		PYY		NKX3-2		Wnt3A
	OE	P-value	OE	P-value	OE	P-value	OE	P-value	OE	P-value	OE	P-value
Age
<55	24/42	0.059	24/42	0.642	31/42	0.668	25/42	0.777	22/42	0.253	28/42	0.519
≥55	25/32		20/32		25/32		18/32		21/32		19/32
Clinical stage
I and II	9/14	0.865	7/14	0.423	9/14	0.270	7/14	0.495	5/14	0.059	10/14	0.494
III and IV	40/60		37/60		47/60		36/60		38/60		37/60
Nodal metastasis
Absent	23/35	0.931	19/35	0.390	10/35	0.420	22/35	0.433	19/35	0.528	20/35	0.281
Present	26/39		25/39		31/39		21/39		24/39		27/39
Distant metastasis
Absent	24/38	0.568	18/38	<0.05^a	23/38	<0.05^a	24/38	0.366	17/38	<0.05^a	23/38	0.583
Present	25/36		26/36		33/36		19/36		26/36		24/36
Chemoresistance
Sensitive	35/55	0.425	31/55	0.356	42/55	0.814	33/55	0.575	28/55	<0.05^a	35/55	0.970
Resistance	14/19		13/19		14/19		10/19		15/19		12/19

^{^a}

, p<0.05.

A sample was considered OE when the immunoreactive score was ≥2 for FOXA2; ≥4 for LEF1, PYY, NKX3-2, and Wnt3A; and ≥6 for VAV3.

OE, overexpression.